120 related articles for article (PubMed ID: 7407335)
1. The absorption of disopyramide in animals determined using a stable isotope co-administration technique.
Haskins NJ; Waddell KA; Ford GC; Spalton PN; Walls CM; Forrest TJ; Palmer RF
Biomed Mass Spectrom; 1980 Feb; 7(2):80-3. PubMed ID: 7407335
[TBL] [Abstract][Full Text] [Related]
2. A stable isotope dilution assay for disopyramide and its [13C, 15N]labelled analogue in biological fluids.
Haskins NJ; Ford GC; Palmer RF; Waddell KA
Biomed Mass Spectrom; 1980 Feb; 7(2):74-9. PubMed ID: 6773595
[TBL] [Abstract][Full Text] [Related]
3. Disopyramide phosphate: tissue uptake and relationship between drug concentrations in the plasma and myocardium of rats.
Karim A; Kook C; Campion J; Doherty M
Arch Int Pharmacodyn Ther; 1977 Aug; 228(2):222-36. PubMed ID: 921413
[TBL] [Abstract][Full Text] [Related]
4. Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.
Bryson SM; Whiting B; Lawrence JR
Br J Clin Pharmacol; 1978 Nov; 6(5):409-19. PubMed ID: 728284
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog.
Karim A; Kook C; Novotney RL; Zagarella J; Campion J
Drug Metab Dispos; 1978; 6(3):338-45. PubMed ID: 26556
[TBL] [Abstract][Full Text] [Related]
6. The effects of urine pH and plasma protein binding on the renal clearance of disopyramide.
Cunningham JL; Shen DD; Shudo I; Azarnoff DL
Clin Pharmacokinet; 1977; 2(5):373-83. PubMed ID: 21054
[TBL] [Abstract][Full Text] [Related]
7. Stereoselectivity in the metabolism of disopyramide enantiomers in rat and dog.
Cook CS; Karim A; Sollman P
Drug Metab Dispos; 1982; 10(2):116-21. PubMed ID: 6124395
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of disopyramide in patients with imminent to moderate cardiac failure.
Landmark K; Bredesen JE; Thaulow E; Simonsen S; Amlie JP
Eur J Clin Pharmacol; 1981 Feb; 19(3):187-92. PubMed ID: 7215416
[TBL] [Abstract][Full Text] [Related]
9. Comparative bioavailability of disopyramide after multiple dosing with standard capsules and controlled-release tablets.
Forssell G; Graffner C; Nordlander R; Nyquist O
Eur J Clin Pharmacol; 1980; 17(3):209-13. PubMed ID: 7363933
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetic and metabolic study of disopyramide in oral and intravenous administration].
De Graeve J; Kremers P; Gielen JE
Therapie; 1977; 32(2):195-204. PubMed ID: 898127
[No Abstract] [Full Text] [Related]
11. Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration.
Haughey DB; Lima JJ
Biopharm Drug Dispos; 1983; 4(2):103-12. PubMed ID: 6882879
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
Aitio ML; Allonen H; Kanto J; Mäntylä R
Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):219-26. PubMed ID: 7095921
[TBL] [Abstract][Full Text] [Related]
13. [Bioavailability of procainamide and disopyramide with and without concomitant administration of an antacid: aluminium phosphate (author's transl)].
Albin H; Vinçon G; Bertolaso D; Dangoumau J
Therapie; 1981; 36(5):541-6. PubMed ID: 7323992
[No Abstract] [Full Text] [Related]
14. Pharmacokinetics of disopyramide administered by intramuscular, intravenous and oral routes to normal volunteers [proceedings].
Ashford JJ; Carmichael D; Kidner PH
Br J Pharmacol; 1979 Jul; 66(3):442P-443P. PubMed ID: 526732
[No Abstract] [Full Text] [Related]
15. Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion.
Lien E; Bakke OM
Br J Clin Pharmacol; 1983 Jul; 16(1):71-6. PubMed ID: 6882625
[TBL] [Abstract][Full Text] [Related]
16. Disopyramide pharmacokinetics and bioavailability.
Dubetz DK; Brown NN; Hooper WD; Eadie MJ; Tyrer JH
Br J Clin Pharmacol; 1978 Sep; 6(3):279-81. PubMed ID: 687507
[No Abstract] [Full Text] [Related]
17. Disopyramide pharmacokinetics during recovery from myocardial infarction.
Bryson SM; Cairns CJ; Whiting B
Br J Clin Pharmacol; 1982 Mar; 13(3):417-21. PubMed ID: 7059444
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment.
Johnston A; Henry JA; Warrington SJ; Hamer NA
Br J Clin Pharmacol; 1980 Sep; 10(3):245-8. PubMed ID: 7437241
[TBL] [Abstract][Full Text] [Related]
19. The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies.
Upton RA; Williams RL
J Pharmacokinet Biopharm; 1986 Aug; 14(4):365-79. PubMed ID: 3772738
[TBL] [Abstract][Full Text] [Related]
20. Species differences in the biotransformation of a new antiarrhythmic agent: disopyramide phosphate.
Karim A; Ranney RE; Kraychy S
J Pharm Sci; 1972 Jun; 61(6):888-93. PubMed ID: 5046104
[No Abstract] [Full Text] [Related]
[Next] [New Search]
